# MMR/MSI in endometrial cancer

5 EU-approved indications in endometrial cancer need a MMR/MSI result: pembrolizumab (advanced), dostarlimab (2nd line, advanced), durvalumab (maintenance, advanced), durvalumab (maintenance, advanced) and olaparib (maintenance, advanced).

## Approved indications

### dMMR / MSI-H

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Durvalumab](https://oncolabels.com/drugs/durvalumab) (Imfinzi) | Mismatch repair deficient (dMMR) | Monotherapy | Maintenance, advanced | After first-line durvalumab + carboplatin and paclitaxel without progression; Candidates for systemic therapy |
| [Dostarlimab](https://oncolabels.com/drugs/dostarlimab) (Jemperli) | MMR/MSI deficient | Monotherapy | 2nd line, advanced | Progressed on or following prior treatment with a platinum-containing regimen |
| [Pembrolizumab](https://oncolabels.com/drugs/pembrolizumab) (Keytruda) | MMR/MSI deficient | Monotherapy | Advanced | Disease progression on or following prior treatment with a platinum-containing therapy in any setting; Not candidates for curative surgery or radiation |

### pMMR / MSS

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Durvalumab](https://oncolabels.com/drugs/durvalumab) (Imfinzi) | Mismatch repair proficient (pMMR) | + olaparib | Maintenance, advanced | After first-line durvalumab + carboplatin and paclitaxel without progression; Candidates for systemic therapy |
| [Olaparib](https://oncolabels.com/drugs/olaparib) (Lynparza) | Mismatch repair proficient | + durvalumab | Maintenance, advanced | After first-line treatment with durvalumab in combination with carboplatin and paclitaxel without progression |

## Label wording

- **Pembrolizumab** (Keytruda), Endometrial cancer, advanced: “advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation;” [SmPC](https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf)
- **Dostarlimab** (Jemperli), Endometrial cancer, 2nd line, advanced: “JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf)
- **Durvalumab** (Imfinzi), Endometrial cancer, maintenance, advanced: “IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)” [SmPC](https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf)
- **Durvalumab** (Imfinzi), Endometrial cancer, maintenance, advanced: “IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf)
- **Olaparib** (Lynparza), Endometrial cancer, maintenance, advanced: “Lynparza in combination with durvalumab is indicated for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/endometrial-cancer/mmr-msi